Welcome

Login

FirstLoad 6/22/2026 5:50:48 AM

FirstLoadOrReset 6/22/2026 5:50:48 AM

LastRefresh 6/22/2026 5:50:48 AM

NextRefresh 6/22/2026 5:51:48 AM

QuestionSession 6/22/2026 6:35:48 AM

EndSession 6/22/2026 6:50:48 AM

ShowRefreshModal False

AllSet True

Loading...

About the trial

This is a shared database for the ASCOT trial and the REMAP-CAP trial.

REMAP-CAP

REMAP-CAP is a Randomized, Embedded, Multifactorial Adaptive Platform trial for hospitalised patients with respiratory tract infections, including COVID-19. The aim of this global trial is to efficiently evaluate a range of interventions to improve outcomes for patients.

ASCOT

ASCOT is a clinical trial that will generate clinical evidence about treatment for COVID-19 that can be applied during the pandemic to reduce mortality or the need for organ support in hospitalised but not yet critically ill patients with COVID-19.

The people behind the software

We are rethinking research tools, globally. That means we can adapt our existing platform to match new ways of thinking—building capacity in support of your existing clinical practices!

Complex trials require dependable solutions. Our flagship product, Spinnaker (this is it), offers you a comprehensive solution that covers all your trial management needs. From stock control and audit log to reporting, user management and compliance – we tailor the platform exactly as you need it for your study. Designed and coded by our expert team, we ensure complete control over configuration and setup. Experience the perfect blend of adaptability and precision with Spinnaker.

You can read more on the Spiral website or contact us on [email protected]

You can get to know us a little better through our blog and social media pages accessed via the logout screen of this trial.

Made with love in New Zealand.